作者
Sven Francque,Pierre Bédossa,Vlad Ratziu,Quentin M. Anstee,Elisabetta Bugianesi,Arun J. Sanyal,Rohit Loomba,Stephen A. Harrison,R. Balabanska,Lyudmila Mateva,Nicolas Lanthier,Naim Alkhouri,Christophe Moreno,Jörn M. Schattenberg,Diana Stefanova-Petrova,Luisa Vonghia,Roman Rouzier,Maëva Guillaume,Alexander Hodge,Manuel Romero‐Gómez,Philippe Huot-Marchand,Martine Baudin,Marie‐Paule Richard,Jean‐Louis Abitbol,Pierre Broqua,Jean‐Louis Junien,Manal F. Abdelmalek
摘要
Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.
毛豆
归尘
杳鸢
ceeray23
吡咯爱成环
MchemG
火星上的菲鹰
cocolu
tuanheqi
挖菜
田様
兼听则明
嗯哼
马小东
大街小巷
领导范儿
cctv18
传奇3
Suzy
科目三
皖公网安备34019202002308
